Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals
- 9 March 2026
- journal article
- Published by Taylor & Francis in Journal of Chemotherapy
- p. 1-11
Abstract
Patients with pancreatic cancer (PC) harboring DNA damage repair genes (DDRg) alterations, particularly BRCA1/2, may benefit from olaparib. Although the phase III POLO trial demonstrated improved progression-free survival (PFS) with olaparib as maintenance therapy in germline BRCA-mutated metastatic PC, real-world data, especially in patients with non-BRCA DDR alterations, remain limited. The objective of this study is to evaluate the real-world effectiveness and safety of olaparib in PC patients harboring DDRg alterations. A multicenter, retrospective observational study was conducted across eight Spanish hospitals. Adult patients with PC and DDRg alterations who initiated olaparib between December 2018 and October 2022 were included. Data were extracted from electronic medical records. PFS and overall survival (OS) were estimated using the Kaplan-Meier method. Adverse events (AEs) were assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A total of 24 patients were included, most commonly harboring gBRCA2 (58.3%), sBRCA2 (16.7%) or ATM (16.7%) alterations. Among patients receiving olaparib as maintenance therapy (87.5%), the objective response rate (ORR) was 33.3%, the median PFS was 10.4 months (95% CI, 1.7-19.1) and the median OS was 32.9 months (95% CI, 20.1-45.6). At data cutoff, the OS rate >20 months was 71.4% and >30 months was 42.9%. Grade ≥3 AEs occurred in 16.7% of patients. This multicenter real-world study olaparib showed clinical activity and acceptable safety profile in PC patients harboring DDRg mutations, including those beyond BRCA. Further studies are needed to validate these findings and to better identify patients who may benefit from olaparib, particularly those with non-BRCA mutations.Keywords
This publication has 25 references indexed in Scilit:
- Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genesFarmacia Hospitalaria, 2025
- Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic VariantsCancer Medicine, 2025
- Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world studyEuropean Journal of Cancer, 2024
- Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II studyESMO Open, 2023
- Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid TumorsJAMA Oncology, 2022
- Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsJAMA Oncology, 2021
- SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)Clinical and Translational Oncology, 2021
- Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationBritish Journal of Cancer, 2019
- Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cellsBritish Journal of Cancer, 2019
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009